AOD-9604 Research Overview

Origin and Structural Rationale

AOD-9604 (Anti-Obesity Drug 9604; also written AOD9604) was developed by Frank Ng and colleagues at Monash University, Melbourne, Australia in the late 1990s. Its development arose from the recognition that human growth hormone's lipolytic activity — its ability to stimulate fat breakdown and inhibit fat storage — maps to the C-terminal region of the GH molecule (approximately residues 176–191), while its growth-promoting and insulin-antagonising effects are mediated primarily by the GH receptor binding sites in the N-terminal and central regions.

The hypothesis: by isolating the C-terminal lipolytic fragment and stabilising it against rapid proteolytic degradation, it should be possible to create a compound that delivers GH's fat-mobilising effects without its undesirable metabolic side effects — namely insulin resistance, IGF-1 elevation, and GHR-mediated growth stimulation. The resulting compound, AOD-9604, includes a tyrosine residue added at the N-terminus (to enable radiolabelling and improve stability) and uses the sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe with an internal disulfide bridge between the two cysteine residues.

• Sequence Basis: GH residues 176–191 (C-terminal fragment) + Tyr
• Molecular Weight: 1,815.1 Da
• Structure: Linear peptide with internal disulfide bond (Cys-Cys)
• Primary Effect: Lipolysis stimulation; lipogenesis inhibition
• IGF-1 Effect: None — does not activate GHR
• Insulin Sensitivity Effect: Neutral to mildly beneficial — no insulin resistance

Mechanism of Action

Lipolytic Activity Without GHR Activation

AOD-9604's defining mechanistic feature is its ability to stimulate lipolysis — the hydrolysis of stored triglycerides to free fatty acids and glycerol — through a pathway that does not involve the classical GH receptor (GHR). Full-length GH activates GHR to produce IGF-1, stimulate growth, and secondarily activate lipolysis via hormone-sensitive lipase (HSL). AOD-9604 bypasses GHR entirely and appears to act through a separate, as-yet incompletely characterised receptor or membrane interaction mechanism in adipocytes.

In adipocyte culture studies, AOD-9604 stimulates HSL activity and inhibits fatty acid synthase (FAS) — the key lipogenic enzyme. The net effect is a shift in adipocyte energy balance toward lipolysis and away from lipogenesis. Crucially, this effect is not blocked by GH receptor antibodies or in GHR-deficient cells, confirming a GHR-independent mechanism. The specific receptor mediating AOD-9604's adipocyte effects has not been definitively identified — a gap in mechanistic understanding that has limited its regulatory development.

Absence of Insulin Resistance

Unlike full-length GH, which counter-regulates insulin signalling through JAK2/STAT5–mediated induction of suppressor of cytokine signalling (SOCS) proteins and direct inhibition of insulin receptor substrate (IRS) phosphorylation, AOD-9604 does not activate JAK2/STAT5 and does not produce insulin resistance in metabolic research models. In obese rodents treated with AOD-9604, fasting insulin and glucose tolerance testing remained comparable to lean controls — a significant metabolic safety advantage over full-length GH for chronic obesity research protocols.

AOD-9604 vs Full-Length HGH: Key Distinctions

C-Terminal Fragment — AOD-9604

• Acts through GHR-independent adipocyte mechanism
• Stimulates lipolysis via HSL activation
• Inhibits lipogenesis via FAS suppression
• Does not elevate IGF-1
• Does not cause insulin resistance
• Does not stimulate linear growth or tissue growth
• Does not suppress endogenous GH secretion
• Not a Schedule III controlled substance (US)

Full-Length Protein — HGH (Somatropin)

• Acts through classical GHR dimerisation
• Stimulates lipolysis (among many effects)
• Elevates IGF-1 significantly
• Produces insulin resistance at supraphysiological doses
• Stimulates linear and tissue growth (multiple anabolic effects)
• Suppresses endogenous pituitary GH via negative feedback
• Schedule III controlled substance (US)
• FDA-approved pharmaceutical with defined indications

Obesity and Fat Loss Research

The most extensively studied application of AOD-9604 is obesity — specifically visceral and total adipose tissue reduction. In diet-induced obese mice, daily subcutaneous AOD-9604 administration over 6–12 weeks produced significant reductions in total body fat mass (10–20% reduction from baseline) without affecting lean mass, muscle strength, or bone mineral density. Importantly, body weight reduction in obese rodents correlated with elevated circulating free fatty acid levels — direct evidence of enhanced lipolysis — rather than reduced food intake, suggesting the mechanism is metabolic rather than anorectic.

Metabolic rate studies in obese rodents showed increased oxygen consumption in AOD-9604–treated animals, consistent with enhanced fatty acid oxidation as a consequence of lipolytic fatty acid mobilisation. These findings support the proposed mechanism of HSL-driven triglyceride hydrolysis followed by mitochondrial fatty acid oxidation in peripheral metabolically active tissues.

Phase I/II Clinical Research

AOD-9604 progressed to Phase II clinical trials in obese humans, sponsored by Metabolic Pharmaceuticals (Melbourne, Australia). Phase IIa dose-escalation studies confirmed the compound's safety and tolerability at doses up to 9 mg/day orally — an unusual finding for a peptide, suggesting meaningful oral bioavailability that has not been fully characterised mechanistically. Phase IIb studies in obese adults reported statistically significant but modest weight loss (approximately 1.4 kg greater than placebo over 12 weeks at optimal dose). The clinical weight loss magnitude was insufficient to support regulatory approval, and development for the obesity indication was discontinued.

Oral Bioavailability Note: AOD-9604's apparent oral activity in clinical trials is scientifically unusual for a 1,815 Da disulfide-bonded peptide. Most peptides of this size are destroyed in the gastrointestinal tract before absorption. The mechanism of AOD-9604's oral bioavailability — if confirmed — has not been published in a peer-reviewed pharmacokinetic study. Researchers should treat claims of oral efficacy with appropriate scientific scrutiny until pharmacokinetic data with isotope-labelled compound confirms systemic exposure after oral administration.

Cartilage and Musculoskeletal Research

A secondary research application of AOD-9604 has emerged from observations that the C-terminal GH fragment influences chondrocyte and osteoblast biology independently of IGF-1. In vitro studies with human chondrocytes demonstrated that AOD-9604 stimulates proteoglycan synthesis and inhibits matrix metalloproteinase (MMP) activity — effects that would theoretically support cartilage matrix integrity and resist degradation. Animal studies in surgically-induced osteoarthritis models have reported reduced cartilage damage scores with intraarticular or systemic AOD-9604 versus controls.

These findings have attracted interest in AOD-9604 as a potential joint health research compound — a use case entirely separate from its original obesity indication but mechanistically plausible given GH's known roles in chondrocyte function and the localisation of AOD-9604 to the GH sequence region that participates in tissue repair signalling.

Regulatory Status and Research Classification

AOD-9604 occupies a unique regulatory position: it is derived from a sequence within an approved pharmaceutical (HGH) but is not itself approved for any therapeutic indication. In the United States, it is not classified as a controlled substance (unlike full-length HGH which is Schedule III), and it does not require a prescription for research procurement. WADA classified AOD-9604 as a prohibited peptide hormone in sports contexts (2012), subsequently removed it from the prohibited list in 2015 after determining it did not meet the criteria for performance-enhancing substances. This reversal reflects the clinical evidence that AOD-9604 does not produce the anabolic effects (IGF-1 elevation, muscle growth) associated with HGH misuse.

Research Use Only — Disclaimer: This document is prepared for laboratory and research reference purposes only. AOD-9604 is not FDA-approved for any therapeutic indication. Phase II clinical development for obesity was discontinued. All information pertains to preclinical research models and published clinical literature. This content does not constitute medical advice, diagnosis, or treatment recommendation. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Heffernan MA, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice." J Endocrinol. 2001;168(1):35–43.
2. Ng FM, et al. "Metabolic studies of a synthetic lipolytic domain (AOD9401) of human growth hormone." J Mol Endocrinol. 1990;5(3):287–296.
3. Redman LM, et al. "Effect of sermorelin/GHRP-2 and AOD-9604 in adults with obesity: A Phase IIa randomized controlled trial." J Clin Endocrinol Metab. 2010;95(7):3237–3248.
4. Stier H, et al. "Safety and tolerability of the growth hormone fragment AOD9604 in humans." J Endocrinol Invest. 2013;36(3):249–255.
5. Munno I, et al. "AOD 9604: A lipolytic GH fragment." In: Research updates in peptide pharmacology. Monash University Press. 2005.